KaloBios, a biopharmaceutical focused on therapeutics that treat respiratory diseases and cancer, filed on Friday with the SEC to raise up to $60 million in an initial public offering. The South San Francisco, CA-based company, which was founded in 2001 and booked $18 million in sales for the 12 months ended 6/30/2012, plans to list on the NASDAQ under the symbol KBIO. Leerink Swann is the sole bookrunner on the deal. No pricing terms were disclosed.
